A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial

Table 4 Baseline demographics by treatment group

Characteristic	Group A N=	Group B N=	Total N=
Age
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Gender
N (Nmissing)
Male, n (%)
Female, n (%)
Ethnicity
White, n (%)
Asian or Asian British, n (%)
Black or Black British, n (%)
Chinese, Japanese, Korean, Indochinese, n (%)
Mixed race, n (%)
Other, n (%)
Smoking status
Current smoker, n (%)
Ex-smoker, n (%)
Non-smoker, n (%)
PPPASI
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Fresh pustule count (palms and soles)
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Fresh pustule count (palms)
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Fresh pustule count (soles)
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Total pustule count (palms and soles)
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
PPP-IGA
N (Nmissing)
Clear
Almost clear
Mild
Moderate
Severe
Participant global assessment
N (Nmissing)
Clear
Almost clear
Mild
Moderate
Severe
Very severe
DLQI
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Pustular psoriasis at non acral sites (BSA)
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Generalised plaque psoriasis – PASI
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
Palmoplantar quality of life instrument
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
EQ 5D- utility score
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max
EQ 5D-VAS
N (Nmissing)
Mean (SD)
Median (IQR)
Min-Max

ISSN: 1745-6215